Literature DB >> 29521661

Spinal anaesthesia with chloroprocaine 1% versus total intravenous anaesthesia for outpatient knee arthroscopy: A randomised controlled trial.

Volker Gebhardt1, Vera Zawierucha, Oliver Schöffski, Anke Schwarz, Christel Weiss, Marc D Schmittner.   

Abstract

BACKGROUND: Both general and spinal anaesthesia with short-acting local anaesthetics are suitable and reliable for knee arthroscopy as an ambulatory procedure. Chloroprocaine (CP) 1% seems to be the ideal spinal local anaesthetic for this indication.
OBJECTIVE: The aim of this study was to compare spinal anaesthesia using CP 1% with general for outpatient knee arthroscopy with regard to procedure times, occurrence of pain, patient satisfaction and recovery, and also costs.
DESIGN: A randomised controlled single-centre trial.
SETTING: University Medical Centre Mannheim, Department of Anaesthesiology and Surgical Intensive Care Medicine, Mannheim, Germany. April 2014 to August 2015. PATIENTS: A total of 50 patients (women/men, 18 to 80 years old, ASA I to III) undergoing outpatient knee arthroscopy were included. A contra-indication to an allocated anaesthetic technique or an allergy to medication required in the protocol led to exclusion.
INTERVENTIONS: Either general anaesthesia with sufentanil, propofol and a laryngeal mask for airway-management or spinal with 40-mg CP 1% were used. We noted procedure times, patient satisfaction/recovery and conducted a 7-day follow-up. MAIN OUTOMES: Primary outcome was duration of stay in the day-surgery centre. Secondary outcomes were first occurrence of pain, patient satisfaction, quality of recovery and adverse effects. In addition, we analysed treatment costs.
RESULTS: Spinal had faster recovery than general anaesthesia with patients reaching discharge criteria significantly earlier [117 min (66 to 167) versus 142 min (82 to 228), P = 0.0047]. Pain occurred significantly earlier in the general anaesthesia group (P = 0.0072). Costs were less with spinal anaesthesia (cost ratio spinal: general 0.57). Patients felt significantly more uncomfortable after general anaesthesia (P = 0.0096).
CONCLUSION: Spinal anaesthesia with 40-mg CP 1% leads to a significantly earlier discharge and is cheaper compared with general. TRIAL REGISTRATION: German Clinical Trials Register, www.drks.de, identifier: DRKS00005989.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29521661     DOI: 10.1097/EJA.0000000000000794

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  5 in total

1.  A randomised, non-inferiority study of chloroprocaine 2% and ropivacaine 0.75% in ultrasound-guided axillary block.

Authors:  Irene Sulyok; Claudio Camponovo; Oliver Zotti; Werner Haslik; Markus Köstenberger; Rudolf Likar; Chiara Leuratti; Elisabetta Donati; Oliver Kimberger
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

2.  A comparative study on the effect of addition of intrathecal buprenorphine to 2-chloroprocaine spinal anesthesia in short duration surgeries.

Authors:  Jayaprakash Siddaiah; Vinayak S Pujari; Ashok S Madalu; Yatish Bevinaguddaiah; Leena H Parate
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2019 Oct-Dec

Review 3.  Spinal anaesthesia for ambulatory surgery.

Authors:  W Rattenberry; A Hertling; R Erskine
Journal:  BJA Educ       Date:  2019-08-13

4.  Randomized Controlled Study Comparing 2-Chloroprocaine and Bupivacaine for Spinal Anesthesia in Gynecological Surgeries.

Authors:  Subin Thomas; Devanand Bhimrao Pawar; Dipakkumar Hiralal Ruparel; Shweta Sedani
Journal:  Anesth Essays Res       Date:  2022-06-14

5.  Spinal anaesthesia with Chloroprocaine HCl 1% for elective lower limb procedures of short duration: a prospective, randomised, observer-blind study in adult patients.

Authors:  Daniela Ghisi; Giorgia Boschetto; Alessandra Maria Spinelli; Sandra Giannone; Jacopo Frugiuele; Marcello Ciccarello; Stefano Bonarelli
Journal:  BMC Anesthesiol       Date:  2021-02-20       Impact factor: 2.217

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.